Cutaneous squamous cell carcinoma - null regimens
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main cutaneous SCC page for regimens that include active anticancer treatment.
Adjuvant therapy
Observation
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Brewster et al. 2007 | 1996-2002 | Phase 3 (C) | Retinoic acid & IFN | Did not meet primary endpoint of TTR or SPT |
No further treatment.
Preceding treatment
References
- Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20;25(15):1974-8. link to original article PubMed
Placebo
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Awaiting publication (R2810-ONC-1788) | 2019-2025 | Phase 3 (C) | Cemiplimab | TBD if different primary endpoint of DFS |
No active antineoplastic treatment.
Preceding treatment
- Surgical resection and RT
References
- R2810-ONC-1788: NCT03969004